Mikrogen Diagnostik recomLine TORCH Screening IgG Lateral Strip Test Kit: Multiplex Serological Assay for Prenatal Diagnostics

The Mikrogen Diagnostik recomLine TORCH Screening IgG Lateral Strip Test Kit is a recombinant immunoblot assay designed for simultaneous, multiplex detection of IgG antibodies to four primary congenital infections grouped under the acronym TORCH — Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV), and Herpes Simplex Virus types 1 and 2 (HSV-1, HSV-2). This kit is engineered for clinical laboratories, maternal-fetal medicine, and epidemiological research where rapid and reliable antibody profiling is required.

Background: TORCH Infections and Congenital Risk

The TORCH complex represents a group of pathogens with the potential to cross the placental barrier, causing congenital infections that can result in miscarriage, neurological damage, growth retardation, and stillbirth. The CDC and American College of Obstetricians and Gynecologists recommend routine prenatal screening for TORCH antibodies, particularly in high-risk pregnancies or populations with limited vaccination coverage.

• Toxoplasma gondii causes severe ocular and neurological damage in fetuses.

• Rubella virus leads to Congenital Rubella Syndrome (CRS) when infection occurs in the first trimester.

• Cytomegalovirus (CMV) is the leading infectious cause of congenital hearing loss.

• Herpes Simplex Virus, particularly HSV-2, is associated with neonatal encephalitis and sepsis-like illness.

Assay Design: Recombinant Antigen Strip Technology

The recomLine TORCH Screening kit is based on lateral flow immunoblot technology using recombinant antigens immobilized on nitrocellulose strips. Serum or plasma samples are applied to the strip, and specific IgG antibodies bind to their corresponding antigens. A secondary alkaline phosphatase-conjugated anti-human IgG detects the bound antibodies, visualized through substrate development.

Technical Specifications:

• Sample type: Serum or plasma

• Incubation time: ~2.5 hours

• Detection: Visual band detection, semi-quantitative

• Antigens: Recombinant proteins for Toxo, Rubella, CMV, HSV-1, HSV-2

• Regulatory status: CE-IVD; RUO in the U.S.

See FDA guidelines for Research Use Only products and CLIA certification standards.

Analytical Performance and Quality

Multiple studies confirm this kit’s high analytical sensitivity and specificity, validated under College of American Pathologists (CAP) and CDC quality standards.

For peer-reviewed validation data, refer to PubMed Central and NIH Genetic Testing Registry.

Clinical Application in Maternal and Neonatal Diagnostics

This assay is particularly effective in:

• Determining immunity to Rubella pre-conception or during early pregnancy

• Diagnosing recent CMV infection in pregnant individuals using avidity profiles

• Identifying HSV serostatus for perinatal management

• Screening transplant candidates and immunocompromised patients for latent infections

Used in accordance with protocols from:

• National Institute of Child Health and Human Development (NICHD)

• Office of Women’s Health (OWH)

• NIH Clinical Trials

Laboratory Implementation and Automation Compatibility

The recomLine TORCH Screening IgG kit is designed for:

• Manual operation

• Semi-automated strip processors

• Densitometry image analysis

The kit is suitable for clinical workflows in:

• University hospitals

• Public health laboratories

• CDC partner labs

Standard operating procedures align with EPA Quality Assurance guidelines and NIH intramural safety protocols.

Global Epidemiology and Surveillance Relevance

This kit is actively used in seroprevalence studies and global surveillance systems supported by:

• USAID Maternal and Child Health

• UNICEF Congenital Infections Data

• NIH Fogarty International Center

It has been featured in longitudinal cohort studies, particularly those tracking the epidemiology of rubella and CMV across developing nations, as seen in research published through NCBI Bookshelf.

Comparison with Alternative Testing Platforms

For comparative assay reviews, consult resources from NLM, NIH Office of Research Infrastructure Programs, and CDC Lab Methods.

Summary: Advantages of the Mikrogen recomLine TORCH Screening IgG Kit

• ✔️ Comprehensive TORCH pathogen coverage in a single test

• ✔️ Accurate serological profiling of IgG response

• ✔️ Validated against global clinical reference standards

• ✔️ Scalable for both small clinics and research institutions

• ✔️ Compliant with international diagnostic regulations

Further documentation and application notes are available from:

• NIH RePORTER

• MedlinePlus Lab Testing Portal

• CDC Prenatal Infections Hub